Pfizer’s experimental GLP-1 candidate berobenatide delivered up to a 15.9% body-weight reduction over eight months in Phase 2b and nearly 15% loss after 14 months on a monthly dose. Novo Nordisk’s oral Wegovy pill has shattered sales forecasts, driving exceptional demand that reinforces its first-mover lead in the weight-loss market.
In the VESPER-1 Phase 2b study, patients on the highest weekly berobenatide dose achieved a 15.9% body-weight reduction over eight months, and VESPER-3 results showed nearly 15% loss after 14 months on a monthly regimen. Pfizer positions berobenatide as the first once-monthly GLP-1 therapy candidate.
Novo Nordisk’s Wegovy pill has shattered sales forecasts following strong uptake from patients preferring oral therapy. Forecasts have been revised higher as Wegovy extends its first-mover advantage beyond weekly injections.
The combination of Pfizer’s promising monthly injection data and Wegovy’s robust performance is set to reshape market dynamics, with pricing and patient retention at stake. Novo Nordisk is advancing multiple Phase 3 obesity and metabolic trials globally in 2026 to sustain its leadership.
